(Q48008575)

7 February 2018

title

S100B serum levels and long-term improvement of negative symptoms in patients with schizophrenia (English)

1 reference

7 February 2018

0 references

5

Volker Arolt

1 reference

7 February 2018

author name string

Matthias Rothermundt

1

1 reference

7 February 2018

Gerald Ponath

2

1 reference

7 February 2018

Thomas Glaser

3

1 reference

7 February 2018

Guenter Hetzel

4

1 reference

7 February 2018

language of work or name

English

0 references

publication date

1 May 2004

1 reference

7 February 2018

published in

Neuropsychopharmacology

1 reference

7 February 2018

volume

29

1 reference

7 February 2018

issue

5

1 reference

7 February 2018

page(s)

1004-1011

1 reference

7 February 2018

https://scigraph.springernature.com/pub.10.1038/sj.npp.1300403

exact match

0 references

cites work

Schizophrenia: breakdown in the well-regulated lifelong process of brain development and maturation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300403

Defining the course of brain structural change and plasticity in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300403

S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300403

The S-100: a protein family in search of a function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300403

Decreased S100-beta protein in schizophrenia: preliminary evidence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300403

Spatial and nonspatial learning in mice: effects of S100 beta overexpression and age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300403

Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300403

Senescence-accelerated overexpression of S100beta in brain of SAMP6 mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300403

A follow-up magnetic resonance imaging study of schizophrenia. Relationship of neuroanatomical changes to clinical and neurobehavioral measures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300403

The neuropathology of schizophrenia. A critical review of the data and their interpretation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300403

Neuropathological studies of synaptic connectivity in the hippocampal formation in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300403

Structural neuroimaging in schizophrenia. An integrative view of neuromorphology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300403

Alterations in synaptic proteins and their encoding mRNAs in prefrontal cortex in schizophrenia: a possible neurochemical basis for 'hypofrontality'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300403

The positive and negative syndrome scale (PANSS) for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300403

Neurochemical sensitization in the pathophysiology of schizophrenia: deficits and dysfunction in neuronal regulation and plasticity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300403

Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300403

Schizophrenia as a disorder of developmentally reduced synaptic connectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300403

Analysis of complex brain disorders with gene expression microarrays: schizophrenia as a disease of the synapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300403

Structural brain imaging in schizophrenia: a selective review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300403

Psychometric properties of the positive and negative syndrome scale (PANSS) in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300403

The neuropathology of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300403

Dynamics of brain-derived proteins in cerebrospinal fluid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300403

Increased S100B blood levels in unmedicated and treated schizophrenic patients are correlated with negative symptomatology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300403

S100B in brain damage and neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300403

S100B in schizophrenic psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300403

Serum S100B is increased during early treatment with antipsychotics and in deficit schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300403

The reduced neuropil hypothesis: a circuit based model of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300403

A review of MRI findings in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300403

Association of neuregulin 1 with schizophrenia confirmed in a Scottish population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300403

Neuregulin 1 and susceptibility to schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300403

Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300403

Neurotoxicity, neuroplasticity, and magnetic resonance imaging morphometry: what is happening in the schizophrenic brain?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300403

Transgenic mice overexpressing the neurotrophic factor S-100 beta show neuronal cytoskeletal and behavioral signs of altered aging processes: implications for Alzheimer's disease and Down's syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300403

Elevated plasma levels of S-100b protein in schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300403

Learning and memory in S100-beta transgenic mice: an analysis of impaired and preserved function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300403

Is schizophrenia a progressive neurodevelopmental disorder? Toward a unitary pathogenetic mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300403

T-maze spontaneous alternation rate is decreased in S100 beta transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300403

7 January 2021

A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300403

7 January 2021

Increased serum S100B protein in schizophrenia: a study in medication-free patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300403

7 January 2021

Five-factor model of schizophrenia. Initial validation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300403

7 January 2021

The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300403

7 January 2021

Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300403

7 January 2021

Identifiers

DOI

10.1038/SJ.NPP.1300403

1 reference

7 February 2018

1 reference

7 February 2018